Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: siRNA therapeutics - Silence Therapeutics

Next Previous
Drug Profile

Research programme: siRNA therapeutics - Silence Therapeutics

Alternative Names: Atu014; Atu093; Atu111; Atu134; Atu150; Atu195; AtuRNAi; Soluble Fms-like Tyrosine Kinase-1-specific SiRNA

Latest Information Update: 05 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atugen AG
  • Developer Charite of Berlin; McGill University; Sanofi; Silence Therapeutics; Silence Therapeutics plc
  • Class Antihyperglycaemics; Antihypertensives; Antineoplastics; Small interfering RNA
  • Mechanism of Action Endothelin A receptor antagonists; Protein kinase N3 inhibitors; RNA interference; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute lung injury; Solid tumours

Highest Development Phases

  • No development reported Acute lung injury; Preeclampsia; Pulmonary arterial hypertension
  • Discontinued Diabetes mellitus; Solid tumours; Wounds

Most Recent Events

  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 28 Oct 2021 No recent reports of development identified for preclinical development in Preeclampsia in England (IV)
  • 28 May 2020 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in England (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top